Inclusion Criteria:

- Femal patient aged > 18 years

- Histologically proven diagnosis of cancer of the ovary, the fallopian tube or
peritoneal

- patients whose disease progresses or relapses

- patients having received at least a line of platinum-based chemotherapy

- patients whose treatment of relapse is envisaged to comprise paclitaxel

- patients who will receive EPO for treatment of their anaemia

- ECOG performans status < 2

- life expectancy > 16 weeks

- patient who has clearly given her consent by signing on informed consent form prior
to participation

Exclusion Criteria:

- peripheral neuropathy grade > 2

- history of ischemic cardiopathy, congestive heart failure (NYHA>2), arrhythmia,
hypertension or significant valvulopathy

- abnormal biological values

- A therapy or a serious disease which could involve a risk for the patient or
interfere with the aims of the study

- patient who is pregnant, breast feeding or using inadequate contraception

- concomitant therapy by a potentially neurotoxic drug

- concomitant inclusion in another therapeutic trial which could interfere with the
aims of the study

- patient who for familial, sociological, geographical or psychological condition could
not be followed correctly